Rifapentine
- Generic Name
- Rifapentine
- Brand Names
- Priftin
- Drug Type
- Small Molecule
- Chemical Formula
- C47H64N4O12
- CAS Number
- 61379-65-5
- Unique Ingredient Identifier
- XJM390A33U
- Background
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
- Indication
For the treatment of pulmonary tuberculosis.
- Associated Conditions
- Active Tuberculosis, Late phase Tuberculosis
Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
- Conditions
- TuberculosisHIV Infections
- Interventions
- First Posted Date
- 2011-07-28
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 3000
- Registration Number
- NCT01404312
- Locations
- 🇺🇸
University of Southern California CRS, Los Angeles, California, United States
🇺🇸University of Washington AIDS CRS, Seattle, Washington, United States
🇺🇸Trinity Health and Wellness Center CRS, Dallas, Texas, United States
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
- Conditions
- TuberculosisTuberculosis, Pulmonary
- Interventions
- First Posted Date
- 2010-07-14
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 37
- Registration Number
- NCT01162486
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis
- Conditions
- Smear Positive, Pan-sensitive, Pulmonary Tuberculosis
- Interventions
- First Posted Date
- 2010-01-07
- Last Posted Date
- 2012-08-17
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 60
- Registration Number
- NCT01043575
- Locations
- 🇺🇬
Uganda / Case Western Reserve Research Collaboration, Kampala, Uganda
🇺🇸Audie L. Murphy VA Medical Center, San Antonio, Texas, United States
🇺🇸Denver Public Health, Denver, Colorado, United States
Study of Daily Rifapentine for Pulmonary Tuberculosis
- Conditions
- Tuberculosis
- Interventions
- First Posted Date
- 2008-12-25
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 153
- Registration Number
- NCT00814671
- Locations
- 🇿🇦
Universiy of Cape Town Lung Institute, Cape Town, Western Cape, South Africa
TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 865
- Registration Number
- NCT00694629
- Locations
- 🇺🇸
Washington DC Veterans Administration Medical Center, Washington DC, District of Columbia, United States
🇪🇸Agencia de Salut Publica, Barcelona, Spain
🇺🇸University of North Texas Health Science Center, Fort Worth, Texas, United States
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
- Conditions
- Mycobacterium Tuberculosis
- Interventions
- First Posted Date
- 2007-04-16
- Last Posted Date
- 2017-12-07
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 15
- Registration Number
- NCT00460759
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
- Conditions
- Tuberculosis
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2008-08-25
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 230
- Registration Number
- NCT00164450
- Locations
- 🇺🇸
University of Southern California Medical Center, Los Angeles, California, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸University of California at San Diego, San Diego, California, United States
Tuberculosis Prevention for HIV Infected Adults
- Conditions
- HIV InfectionsTuberculosis
- Interventions
- First Posted Date
- 2003-03-28
- Last Posted Date
- 2012-10-22
- Target Recruit Count
- 1148
- Registration Number
- NCT00057122
- Locations
- 🇿🇦
Chris Hani Baragwanath Hospital, Soweto, South Africa
TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
- Conditions
- Tuberculosis
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 150
- Registration Number
- NCT00023426
- Locations
- 🇺🇸
Thomas Street Clinic, Houston, Texas, United States
🇺🇸New York University School of Medicine, New York, New York, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
- Conditions
- Tuberculosis
- First Posted Date
- 2001-09-10
- Last Posted Date
- 2005-09-13
- Lead Sponsor
- Centers for Disease Control and Prevention
- Target Recruit Count
- 36
- Registration Number
- NCT00023387
- Locations
- 🇺🇸
LA County/USC Medical Center, Los Angeles, California, United States
🇺🇸Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States
🇺🇸Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.